A Study of Systemic Hedgehog Antagonist With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer - Related Studies

A Study of Systemic Hedgehog Antagonist With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

This study is currently recruiting participants.

Study NCT00636610. Last updated on June 26, 2008. Information provided by Genentech

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Metastatic Colorectal Cancer

2	Additional conditions recognized in this trial
		Colorectal Neoplasms

3	More general conditions related to this trial
		Colonic Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Intestinal Diseases
		Intestinal Neoplasms
		Neoplasms
		Neoplasms by Site
		Rectal Diseases

4	Interventions listed in this trial
		GDC-0449
		placebo
		bevacizumab
		chemotherapy

5	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Antineoplastic Agents
		Growth Inhibitors
		Growth Substances
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		Genentech